Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: A pooled analysis of 10 case series

Clinical Genitourinary Cancer

Volumn 13, Issue 3, 2015, Pages 193-198

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Lonati, Veronica ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

Abiraterone; Castration resistant prostate cancer; Docetaxel; Enzalutamide; Pretreated

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN; TAXOID;

ANTIANDROGEN THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASE STUDY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; FATIGUE; HUMAN; MALE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT DURATION; AGED; ANALOGS AND DERIVATIVES; META ANALYSIS; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ABIRATERONE ACETATE; AGED; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 84929073234     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.10.006     Document Type: Review

References (35)

1. J.S. de Bono, S. Oudard, and M. Ozguroglu et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
2. K. Fizazi, H.I. Scher, and A. Molina et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 13 2012 983 992
3. H.I. Scher, K. Fizazi, and F. Saad et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
4. R. Ferraldeschi, N. Sharifi, R.J. Auchus, and G. Attard Molecular pathways: inhibiting steroid biosynthesis in prostate cancer Clin Cancer Res 19 2013 3353 3359
5. X.Y. Zhao, P.J. Malloy, and A.V. Krishnan et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor Nat Med 6 2000 703 706
6. Y. Li, S.C. Chan, and L.J. Brand et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines Cancer Res 73 2013 483 489
7. M. Nakazawa, E.S. Antonarakis, and J. Luo Androgen receptor splice variants in the era of enzalutamide and abiraterone Horm Cancer 5 2014 265 273
8. B. Sahu, M. Laakso, and P. Pihlajamaa et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells Cancer Res 73 2013 1570 1580
9. J. Richards, A.C. Lim, and C.W. Hay et al. Interactions of abiraterone, eplerenone, and prednisolone with wild type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 72 2012 2176 2182
10. B.S. Carver, C. Chapinski, and J. Wongvipat et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
11. Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol, Published online August 6, 2014; http://dx.doi.org/10.1016/j.eururo.2014.07.028.
12. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol, Published online July 10, 2014; http://dx.doi.org/10.1016/j.eururo.2014.06.045.
13. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Int J Surg 8 2010 336 341
14. S. Badrising, V. van der Noort, and I.M. van Oort et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment Cancer 120 2014 968 975
15. G.S. Sandhu, R.A. Parikh, L.J. Appleman, and D. Friedland Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC) (abstract 240) J Clin Oncol 32 suppl 4 2014
16. M.C. Scholz, R.Y. Lam, J.S. Turner, K.N. Chau, L.K. Becker, and C.U. Felarca Enzalutamide in men with prostate cancer resistant to docetaxel and abiraterone (abstract 247) J Clin Oncol 32 suppl 4 2014
17. D. Thomson, N. Charnley, and O. Parikh Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): results from an expanded access program (abstract 188) J Clin Oncol 32 suppl 4 2014
18. F.E. Vera-Badillo, R. Leibowitz-Amit, and A. Templeton et al. Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience (abstract 159) J Clin Oncol 32 suppl 4 2014
19. R. Stevenson, D.G. Fackrell, and D. Ford et al. The sequential use of abiraterone and enzalutamide in metastatic castrate resistant prostate cancer patients: experience from seven U.K. centers (abstract 125) J Clin Oncol 32 suppl 4 2014
20. E. Bournakis, R. Gyftaki, and E. Kafantari et al. Enzalutamide (ENZA) in heavily pretreated patients with bone metastatic castration resistant prostate cancer (mCRPC) resistant to androgen biosynthesis inhibitor (ABI) treatment - the Hellenic experience of the Name Patient Access Program (NPAP) Eur J Cancer 49 suppl 2 2013 S699
21. H.H. Cheng, R. Nadal, and R. Gulati et al. The effect of prior abiraterone (Abi) use on the activity of enzalutamide (Enza) in men with mCRPC (abstract 18) J Clin Oncol 32 suppl 4 2014
22. R.J. van Soest, M.E. van Royen, and E.S. de Morrée et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer 49 2013 3821 3830
23. C.J. Pezaro, A.G. Omlin, and A. Altavilla et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
24. Sella A, Sella T, Peer A, et al. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castration-resistant prostate cancer. Clin Genitourin Cancer, Published online June 10, 2014; http://dx.doi.org/10.1016/j.clgc.2014.06.007.
25. Al Nakouzi N, Le Moulec S, Albigès L, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol, Published online May 2, 2014; http://dx.doi.org/10.1016/j.eururo.2014.04.015.
26. O. Caffo, G. Pappagallo, and S. Brugnara et al. Multiple rechallenges for castration-resistant prostate cancer patients responding to firstline docetaxel: assessment of clinical outcomes and predictive factors Urology 79 2012 644 649
27. M.M. Heck, M. Thalgott, and M. Retz et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer BJU Int 110 2012 E635 E640
28. Y. Loriot, C. Massard, and M. Gross-Goupil et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer Eur J Cancer 46 2010 1770 1772
29. K.L. Noonan, S. North, R.L. Bitting, A.J. Armstrong, S.L. Ellard, and K.N. Chi Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide Ann Oncol 24 2013 1802 1807
30. Y. Loriot, D. Bianchini, and E. Ileana et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol 24 2013 1807 1812
31. A. Omlin, C.J. Pezaro, and S. Zaidi et al. Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer Br J Cancer 109 2013 1079 1084
32. Clinicaltrials.gov [Web site]. A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02116582. Accessed: August 16, 2014.
33. Clinicaltrials.gov [Web site]. Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01949337. Accessed: August 16, 2014.
34. Clinicaltrials.gov [Web site]. Sequencing Abiraterone and Enzalutamide in mCRPC. Available at: http://www.clinicaltrials.gov/ct2/show/NCT02125357. Accessed: August 16, 2014.
35. T.M. Beer, A.J. Armstrong, and D.E. Rathkopf et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433